The researchers said their new study supports the clinical utility of their test, which combines genomic and drug screening analyses of organoids to guide cancer treatment.
By screening more than 1,500 drugs against patient-derived glioblastoma cells, researchers tracked down tumor alterations with apparent ties to proteasome inhibitor response.
The firms are targeting a compatible offering for single-cell gene expression screens following CRISPR-based editing, with applications in drug discovery.
The new method, called sci-Plex, combines nuclear hashing and improved single-cell combinatorial indexing RNA-seq to profile the transcriptional response of single cells.
The Seattle-based firm will use the funding to improve AI integration and further develop its Paris 3D tumor organoid diagnostic and drug discovery platform.
Using genomic data from large cancer cell line collections, investigators identified versions of spliced genes that spell better or worse drug response.
President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.
